Member Info for ratcliffewriter

From the very latest 401 update RNS - London, UK., 14 June 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the VAL401 commercial development.

The VAL401 clinical trial and data collection is now complete and the regulatory process is moving towards completion with the Clinical Study Report on schedule for submission within the regulatory timeframe of two years from trial approval (July 2018). These current and future development updates now focus on the commercial aspects of the completed science development.

So where does this mention anything about approval to phase 3? I have money waiting to invest if you can reconcile the rampers' fog with the lacklustre RNSs. But after Chelsea7's exhaustive trawling it looks very much like 201 is a dose escalation dead duck, and I await his work on 401. (101 looked pretty much a non-starter from what the RNSs said too).

Stick to RNSs indeed - Chelsea7 has posted this morning after a lot of research it seems. Doesn't inspire confidence in 201. Or 101.

'Should', not 'must...?

It's a 'bel prix.'

I think that clarifies it - and it is a sufficiently specialised field that they won't be in individual silos. I'm wondering how long it will be before one of the more negatively inclined says 'but it's a shared Nobel prize so he hasn't even got a full one to himself.' Seriously though, this shows the really top class circles that Scancell's science is moving in. These people don't waste effort on lost causes methinks.

From that link you posted C7 - Homocitrulline has been suggested as a confounding antigen for rheumatoid arthritis antibodies targeting citrullinatedproteins/peptides. Ever more promising work from LD and co.

The below links on the general activity of Roche are interesting, but they get into a much more interesting focus when you realise how Roche are so very close to Scancell with the Grand Challenge/Moditope activity. Remind yourselves of the words in the Hardman Report in relation to the interweaving of BioNtech, Scancell and Roche -Under the heading "BioNTech" - 'Scancell has attracted a sound partner in personalised medicine which represents a strong validation for its technology. Founded in 2008, BioNTech has become Europe’s biggest privately-held biopharmaceutical company. It has a strong focus on the development of targeted and personalised mRNA vaccines and immunotherapies, ranging from innovative CAR-T and TCR-based products to novel antibody checkpoint immunomodulators and small molecules.
Since inception, BioNTech has attracted strong partners, notably Roche/Genentech, Eli Lilly, Sanofi, and Genmab, with deals worth nearly $1bn, the most recent being a $310m deal with Roche to test BioNTech’s m-RNA vaccine in combination with Roche’s recently launched CPI, Tecentriq (2017 sales $495m).'

Then cast an eye over the links below:

https://seekingalpha.com/article/4208039-cancer-highlight-roche-seeks-change-game-liquid-biopsy-platform?dr=1

https://seekingalpha.com/article/4208456-roche-holding-ltd-rhhby-management-virtual-pipeline-event-2018-world-conference-lung-cancer?part=single

https://seekingalpha.com/news/3393720-roche-acquires-tusk-therapeutics-655m?dr=1#email_link

Tusk attracted a price of 70 million euros upfront and up to 585 million euros in milestones, but look how early their products are in their pipeline - https://www.tusktherapeutics.com/#products-pipeline

Slippage in timescales? Yeah, sure. Things taking a long time? Yup. Investor frustration? Understandable - but only PIs it seems. Lack of communication? I think they could do better in that area. But sell up and give up? Definitely not (IMO, of course) - but there's certainly a lot going on, and IMO positively and uniquely too.

Sadly it is just another plug for abcam by nom. Must be about the 6th or 8th time he's done it. Still, he'll probably be off round the other boards he plagues for a few days before returning here like a bad smell.

Mentions being proud of being involved in this trial - our turn next! https://journals.lww.com/oncology-times/Fulltext/2018/09200/Combination_Immunotherapy_Shrinks_Melanoma_Brain.11.aspx

Each to their own, fair enough.

Low key PR is frustrating, but better than trying to make silk purses out of sows' ears like we see others doing. One thing for sure, there's a lot going on.

Mind you Napolean, who was it who said in June this year 'Soon it will be moditope making all the headlines'? Oh, it was you!

Reading your last post I suspect you are a rather lonely individual deep down. Maybe you should take more water with your evening tipple.

At least we now have a fixed date rather than just a month or season as we had before. And it talks if recipients in the plural, so at least 2 or maybe at least 4 as last year. The chances get better even without the excellent science.

TF! Filter you? Heaven forbid dear boy - your posts take me back to my prep school. Entertaining yet curiously pitiful.

TF - why not filter him and anyone else you don't agree with, until you have an environment where you feel unchallenged. Sounds like you've done exactly that on the other board, so why not here? I'm sure that would be to the benefit of many, don't you think?

There is a tendency to interpret posts in different ways, and without wanting to have a weekend of argument after a week of better activity, I have to say I felt roses' posts in the week were true to form, so to speak. TF I have pretty much given up on finding much sense in, but it looks like C7 is in for another 100 lines from the demon headmaster.

Still pushing abcam I see, both here and on Val - Nommy has been neglecting Sar lately, but I'm sure the eternal round will continue for whatever reason.

You can't beat a spontaneous jump.

At least for possibly the first time ever we can be sure that today's 1 trade heralds the arrival of an RNS because we have had an RNS confirming it.